Human melanoma cells do not express Fas (Apo-1/CD95) ligand (Q36454464)

14 August 2017

Human melanoma cells do not express Fas (Apo-1/CD95) ligand (English)

1 reference

14 August 2017

D B Chappell

1

1 reference

14 August 2017

T Z Zaks

series ordinal

2

1 reference

14 August 2017

S A Rosenberg

series ordinal

3

1 reference

14 August 2017

N P Restifo

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

14 August 2017

1 reference

14 August 2017

59

1 reference

14 August 2017

1

1 reference

14 August 2017

59-62

1 reference

Regulation of the proinflammatory effects of Fas ligand (CD95L).

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Gene transfer of Fas ligand induces tumor regression in vivo

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

The role of the Caspase family of cysteine proteases in apoptosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Tumor vaccines--a reality at last?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2239006

Immunology. Ways around rejection

21 September 2018

1 reference

12 December 2020

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

12 December 2020

Antitumor effect of locally produced CD95 ligand

1 reference

12 December 2020

Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases

1 reference

12 December 2020

Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes

1 reference

12 December 2020

Sequential development of structural and functional alterations in T cells from tumor-bearing mice

1 reference

12 December 2020

Immune response and myoblasts that express Fas ligand

1 reference

12 December 2020

Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies

1 reference

12 December 2020

Immunotherapy of melanoma

1 reference

12 December 2020

Identifiers

1 reference

14 August 2017

1 reference